 Continuous lymphokine-activated killer cells advanced cancer National Biotherapy Study Group trial multicenter phase II trial continuous-infusion recombinant lymphokine-activated killer LAK cells Patients advanced cancer measurable disease good performance level Treatment continuous infusion day rest days leukapheresis cells vitro augmentation cellular cytotoxicity days infusion reinfusion LAK cells successive days Therapy weeks patients males median age years Eighty-two percent oncology units intensive care units patients month therapy renal cell carcinoma response rate patients median survival months melanoma response rate patients median survival months histologies response rate patients median survival months responders asymptomatic therapy trial feasibility continuous LAK cells intensive care unit environment Antitumor activity melanoma similar multicenter trials bolus LAK cells Activity renal cell cancer